A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
Completed · Phase 1
Conditions studied: Schizophrenia
In brief
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia and assess whether it changes: * how the body processes (uses) glucose (blood sugar) * how much insulin the pancreas can make. Insulin is a hormone that lowers blood sugar levels in the body. The information from this study will help to understand any effect the study medication may have on how the body uses and stores glucose. This study is accepting both male and female subjects. It will be held in approximately 6 locations in the United States. Participation could last up to 12 weeks.
Key facts
- Study ID
- NCT05463770
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- People needed
- 15
- Starts
- 2022-08-30
- Expected to finish
- 2023-08-22
- Last updated by the study team
- 2024-06-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Woodland International Research Group, LLC — Little Rock, Arkansas, United States
- Woodland Research Northwest, LLC — Rogers, Arkansas, United States
- Collaborative Neuroscience Research, LLC — Long Beach, California, United States
- Catalina Research Institute LLC — Montclair, California, United States
- CNRI - San Diego LLC — San Diego, California, United States
- Galiz Research — Hialeah, Florida, United States
- Neuro-Behavioral Clinical Research, Inc. — North Canton, Ohio, United States
- Pillar Clinical Research, LLC — Richardson, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.